The majority of FTM transgender individuals retain a cervix and can therefore develop cervical cancer. Because of this, national guidelines recommend that transgender men with a cervix follow the same screening protocol as non-transgender women. However, a recent research study found that Fenway Health patients who identify on the female-to-male (FTM) transgender spectrum have over 10 times higher odds of having an inadequate Papanicolaou (Pap) test compared to female patients. In this webinar, experts in the fields of medicine and research will share primary and secondary cervical cancer prevention strategies and will identify strategies that providers can use to address barriers to optimal screening and prevention in FTM patients.
Recorded Webinar – If You Have It, Check It: Overcoming Barriers to Cervical Cancer Screening with Patients on the Female-to-Male Transgender Spectrum 1 Evaluation